COVID-19, Vaccines, BREXIT and Vaccine Damage Claims
In the wake of the COVID-19 pandemic, the European Pharmaceutical Law Review (EPLR) has establish a series for expert insights into the EU and Member State responses to this public health crisis, focussing on pharmaceutical and medical device law and policy.
As part of this series, the EPLR has published an expert insight from Adam Heppinstall on the regulatory aspects of the quest for a COVID-19 Vaccine in the UK, particularly in the light of Brexit. He also considers the possibility of vaccine damage claims arising out of any novel vaccine. Adam is Junior Counsel to the Crown (Civil, A Panel) and a product liability specialist. He appeared in the Court of Appeal for the UK Government in the first vaccine damage payment scheme case to go on appeal (relating to the H1N1 pandemic vaccine), as well as for GSK in the long running Seroxat pharmaceutical group action case. He regularly advises the Department of Health, MHRA and a number of pharmaceutical and medical device companies on a range of product liability and regulatory issues.
The full article can be found here.